NIAGEN BIOSCIENCE INC (NAGE) Stock Price, Quote, News and Overview
NASDAQ:NAGE - Nasdaq - US1710774076 - Common Stock - Currency: USD
NAGE Quote, Performance and Key Statistics
9.82
+0.09 (+0.92%)
The current stock price of NAGE is 9.82 USD. In the past month the price decreased by -12.79%.
NAGE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.12 | 174.55B | ||
| DHR | DANAHER CORP | 26.53 | 143.04B | ||
| A | AGILENT TECHNOLOGIES INC | 21.14 | 32.42B | ||
| IQV | IQVIA HOLDINGS INC | 15.7 | 30.62B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 30.72 | 26.11B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 34.53 | 17.28B | ||
| WAT | WATERS CORP | 22.84 | 16.62B | ||
| ILMN | ILLUMINA INC | 22.78 | 15.00B | ||
| MEDP | MEDPACE HOLDINGS INC | 33.44 | 12.63B | ||
| ICLR | ICON PLC | 12.07 | 12.42B | ||
| TEM | TEMPUS AI INC | N/A | 10.53B | ||
| QGEN | QIAGEN N.V. | 20.43 | 10.40B |
Related stock screener links
About NAGE
Company Profile
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. The company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Company Info
NIAGEN BIOSCIENCE INC
10900 Wilshire Blvd Suite 600
Los Angeles CALIFORNIA US
Employees: 104
Phone: 13103886706
NIAGEN BIOSCIENCE INC / NAGE FAQ
What is the stock price of NIAGEN BIOSCIENCE INC today?
The current stock price of NAGE is 9.82 USD. The price increased by 0.92% in the last trading session.
What is the ticker symbol for NIAGEN BIOSCIENCE INC stock?
The exchange symbol of NIAGEN BIOSCIENCE INC is NAGE and it is listed on the Nasdaq exchange.
On which exchange is NAGE stock listed?
NAGE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NIAGEN BIOSCIENCE INC stock?
11 analysts have analysed NAGE and the average price target is 15.42 USD. This implies a price increase of 57.05% is expected in the next year compared to the current price of 9.82. Check the NIAGEN BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NIAGEN BIOSCIENCE INC worth?
NIAGEN BIOSCIENCE INC (NAGE) has a market capitalization of 773.52M USD. This makes NAGE a Small Cap stock.
How many employees does NIAGEN BIOSCIENCE INC have?
NIAGEN BIOSCIENCE INC (NAGE) currently has 104 employees.
What are the support and resistance levels for NIAGEN BIOSCIENCE INC (NAGE) stock?
NIAGEN BIOSCIENCE INC (NAGE) has a support level at 9.31 and a resistance level at 9.83. Check the full technical report for a detailed analysis of NAGE support and resistance levels.
Is NIAGEN BIOSCIENCE INC (NAGE) expected to grow?
The Revenue of NIAGEN BIOSCIENCE INC (NAGE) is expected to grow by 27.01% in the next year. Check the estimates tab for more information on the NAGE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NIAGEN BIOSCIENCE INC (NAGE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NAGE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NAGE, evaluating the profitability, health, valuation and growth aspects
- NIAGEN BIOSCIENCE INC (NAGE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NIAGEN BIOSCIENCE INC (NAGE) Sales and EPS estimates to see what analysts future expectations are.
- NIAGEN BIOSCIENCE INC (NAGE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NIAGEN BIOSCIENCE INC (NAGE) Insider and Institutional Ownership to learn about the owners and their transactions.
- NIAGEN BIOSCIENCE INC (NAGE) Stock Chart to make your own analysis
- NIAGEN BIOSCIENCE INC (NAGE) Latest news and press-releases to stay up to date.
Does NIAGEN BIOSCIENCE INC (NAGE) stock pay dividends?
NAGE does not pay a dividend.
When does NIAGEN BIOSCIENCE INC (NAGE) report earnings?
NIAGEN BIOSCIENCE INC (NAGE) will report earnings on 2025-10-29, after the market close.
What is the Price/Earnings (PE) ratio of NIAGEN BIOSCIENCE INC (NAGE)?
The PE ratio for NIAGEN BIOSCIENCE INC (NAGE) is 46.76. This is based on the reported non-GAAP earnings per share of 0.21 and the current share price of 9.82 USD. Check the full fundamental report for a full analysis of the valuation metrics for NAGE.
What is the Short Interest ratio of NIAGEN BIOSCIENCE INC (NAGE) stock?
The outstanding short interest for NIAGEN BIOSCIENCE INC (NAGE) is 6.76% of its float. Check the ownership tab for more information on the NAGE short interest.
NAGE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NAGE.
NAGE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to NAGE. While NAGE has a great health rating, its profitability is only average at the moment.
NAGE Financial Highlights
Over the last trailing twelve months NAGE reported a non-GAAP Earnings per Share(EPS) of 0.21. The EPS increased by 1150% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.07% | ||
| ROA | 17.34% | ||
| ROE | 25.49% | ||
| Debt/Equity | 0 |
NAGE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to NAGE. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 32.6% and a revenue growth 27.01% for NAGE